The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•7 March 2026•

1 min read

Novo Nordisk to Sell Wegovy on Hims & Hers Platform; HIMS Shares Surge 40%

Key Facts

1Novo Nordisk plans to sell its weight-loss drug Wegovy on the Hims & Hers Health platform.

2Hims & Hers (HIMS) shares surged nearly 40% in after-hours trading following the report.

Novo Nordisk has reportedly entered into a strategic partnership with telehealth provider Hims & Hers Health to distribute its blockbuster weight-loss drug, Wegovy. The move marks a significant shift in strategy, effectively ending a long-standing legal and commercial dispute regarding patent infringement and compounded GLP-1 alternatives. Following the announcement, shares of Hims & Hers (HIMS) skyrocketed nearly 40% in after-hours trading, while Novo Nordisk (NVO) ADRs saw a modest gain of 2%. This collaboration allows Novo Nordisk to leverage Hims & Hers' extensive digital pharmacy network to reach a broader consumer base. For Hims & Hers, the deal provides a stable supply of branded medication amidst increasing regulatory scrutiny of compounded drug versions. Analysts view this development as a major win for both companies, resolving legal uncertainties and solidifying their positions in the high-growth obesity treatment market.